University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
J

The Big Question in CLL Frontline Therapy: How to Choose Between Ibrutinib, Acalabrutinib & Venetoclax?

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
272 views
May 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
CLL Therapy in 2019
13:16
University of Miami's 2nd Biennial Miami Leukemia Symposium

Advances in the CLL Frontline Therapy: BTK Inhibitors vs. Chemoimmun…

Feat. J. Woyach
07:09
University of Miami's 2nd Biennial Miami Leukemia Symposium

The Big Question in CLL Frontline Therapy: How to Choose Between Ibr…

Feat. J. Woyach
24:51
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Combination Therapies in R/R CLL: Venetoclax +R, Vene…

Feat. M. Davids